The quality of our investors and their contribution to our Board of Directors and Scientific Advisory Board is a key driver of our success.

In 2012, Karus secured a Series B investment that was led by new investors, SV Life Sciences, New Leaf Ventures, Novo A/S and International Biotechnology Trust, who joined existing investors, IP Group and a number of Business Angels. This £25m ($39m) investment is being used to advance the company's proprietary PI3K-p110δ/β and HDAC6 inhibitors through early efficacy trials.